Daunorubicin, Cytarabine, and Venetoclax for Acute Myeloid Leukemia

Study start date: February 1, 2025

Inclusion Criteria:(All of the following criteria must be met.) Patients with newly diagnosed AML based on FAB classification and flow cytometry standards who are eligible for intensive chemotherapy: * Age between 18 and 59 years; * Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or 3; * Expected survival time of ≥3 months; * None of the following severe cardiac, pulmonary, hepatic, or renal conditions: * History of heart disease requiring treatment for congestive heart failure, or an ejection fraction ≤50%, or chronic stable angina; * Pulmonary diffusing capacity of carbon monoxide (DLCO) ≤65%, or forced expiratory volume in 1 second (FEV1) ≤65%; * Moderate liver impairment with total bilirubin \>1.5 to ≤3.0 × the upper limit of normal (ULN); * Creatinine clearance ≥30 mL/min to \<45 mL/min; * Has not received radiotherapy, chemotherapy, targeted therapy, or hematopoietic stem cell transplantation within 4 weeks prior to enrollment; * Has other comorbidities that, in the physician's judgment, make intensive chemotherapy unsuitable; * Is capable of understanding and willing to sign the informed consent form for this study. Exclusion Criteria:(Any of the following criteria will exclude the patient from participation) * Presence of other malignancies; * Prior treatment with venetoclax or azacitidine; * History of angioplasty or stent placement within 12 months prior to signing the informed consent, or a history of myocardial infarction, unstable angina, or other clinically significant heart disease; * Clinically uncontrolled active infection (including bacterial, fungal, or viral infections); * Pregnant or breastfeeding women; * Participation in any other clinical trial within 3 months prior to signing the informed consent; * Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.